Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries

J Cohen, A Beaubrun, R Bashyal, A Huang, J Li… - AIDS research and …, 2020 - Springer
Background Once-daily, single-tablet regimens (STRs) have been associated with improved
patient outcomes compared to multi-tablet regimens (MTRs). This study evaluated real world …

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in …

L Taramasso, A Di Biagio, N Riccardi, F Briano… - PLoS …, 2019 - journals.plos.org
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate
(TDF), but a less favorable effect on lipids. Aim of this retrospective multicentre study was to …

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort …

A Giacomelli, F Conti, L Pezzati, L Oreni… - BMC Infectious …, 2021 - Springer
Background We aimed to assess the overall cardiovascular and metabolic effect of the
switch to three different single tablet regimens (STRs)[tenofovir alafenamide/emtricitabine …

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines

K El Bouzidi, S Jose, AN Phillips, A Pozniak… - Aids, 2020 - journals.lww.com
Objective: To investigate the characteristics and outcomes of people who initiated different
antiretroviral therapy (ART) regimens during the era of integrase strand transfer inhibitors …

First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability …

L Taramasso, A Di Biagio, F Maggiolo, A Tavelli… - HIV …, 2018 - Wiley Online Library
Objectives The aim of this study was to compare the durabilities of efavirenz (EFV) and
rilpivirine (RPV) in combination with tenofovir/emtricitabine (TDF/FTC) in first‐line regimens …

Efficacy and safety of the switch of Triumeq® to generic (abacavir+ lamivudine)+ Tivicay®: data at 24 weeks

J Olalla, J Pérez-Stachowski, B Tortajada… - BMC Pharmacology and …, 2018 - Springer
Background Generic drugs may help to support antiretroviral treatment. We want to assess
the efficacy and safety at 24 weeks of the change of coformulated (abacavir+ lamivudine+ …

Long-term effectiveness of rilpivirine-based single-tablet regimens in a seven-year, two-center observational cohort of people living with HIV

L Taramasso, S Lo Caputo, L Magnasco… - AIDS Research and …, 2022 - liebertpub.com
Data on the long-term durability of rilpivirine (RPV) are still scarce. A two-center
retrospective study was performed, including all people living with HIV (PLWH) treated with …

Tolerability of four‐drug antiretroviral combination therapy in primary HIV‐1 infection

JE Burns, W Stöhr, S Kinloch‐De Loes, J Fox… - HIV …, 2021 - Wiley Online Library
Objectives Rapid initiation of antiretroviral therapy (ART) is important for individuals with
high baseline viral loads, such as in primary HIV‐1 infection (PHI). Four‐drug regimens are …

Prevalence of HLA-B* 5701 in a Kenyan population with HIV infection

R Shah, H Nabiswa, N Okinda, G Revathi… - Journal of …, 2018 - ecommons.aku.edu
We read with interest the article published in your Journal entitled “Real-world persistence
with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort …

Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy

V Perrone, M Dovizio, D Sangiorgi, M Andretta… - International Journal of …, 2023 - mdpi.com
This real-world analysis conducted on administrative databases of a sample of Italian
healthcare entities was aimed at describing the role of therapeutic pathways and drug …